{"product_id":"aqst-pestle-analysis","title":"(AQST) Aquestive Therapeutics, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Aquestive Therapeutics, Inc. PESTLE Analysis helps you quickly assess political, economic, social, technological, legal, and environmental factors shaping the company’s outlook; the page includes a real preview\/sample so you can judge style and depth before buying. Purchase the full report to receive the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS FDA pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. depends on FDA review, labeling, and post-approval oversight for every product, so its film and complex-molecule programs face full CMC and safety checks like other prescription drugs. Standard FDA reviews run up to 10 months and priority reviews 6 months, so any slip can push revenue and milestone cash into later quarters. That risk matters because a label change can alter commercial use overnight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpioid policy pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuboxone, a buprenorphine\/naloxone treatment, sits in a tightly regulated opioid market. The federal X-waiver was ended in 2023, which widened prescribing access, while CDC provisional data show 80,391 U.S. overdose deaths in 2024, keeping treatment demand high. Still, diversion-control rules, prior authorization, and state coverage changes can shift payer behavior and prescribing patterns fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRare-disease policy can support Aquestive Therapeutics, Inc.’s Libervant, Sympazan, and Exservan, since U.S. rare diseases affect about 30 million people and often need specialty prescribers plus payer support. Still, coverage gaps matter: orphan medicines can face high prior-authorization hurdles, and even in 2025 reimbursement delays can slow uptake in epilepsy and ALS care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational market regulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. sells and develops products in the United States and abroad, so it faces separate approval, pricing, and distribution rules in each market. That matters because launch timing can move by country, and geopolitical shifts can delay cross-border plans. In 2025, this kind of regulatory split still affects how fast the company can scale outside the U.S.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo-market exposure raises rule complexity.\u003c\/li\u003e\n\u003cli\u003eEach country sets its own approval path.\u003c\/li\u003e\n\u003cli\u003ePricing and launch timing can shift fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic health priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.’s nausea, severe allergy, opioid dependence, and seizure-rescue products fit core public health needs, especially in emergency care and chronic disease management. U.S. opioid deaths still exceed 100,000 a year, so government focus can support adoption. Still, Medicaid and other public-program budget shifts can move demand fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMatches emergency and chronic care needs\u003c\/li\u003e\n\u003cli\u003ePolicy support can lift adoption\u003c\/li\u003e\n\u003cli\u003ePublic budget cuts can hurt demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and DEA Policy Could Make or Break Aquestive’s Launch Timing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. is highly exposed to FDA and DEA policy, so any delay in review, labeling, or controlled-substance oversight can push launches and cash flow. The 2023 end of the X-waiver widened buprenorphine access, but diversion rules and payer controls still shape Suboxone demand. Public health policy also matters: CDC provisional data show 80,391 U.S. overdose deaths in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review\u003c\/td\u003e\n\u003ctd\u003e6-10 months\u003c\/td\u003e\n\u003ctd\u003eLaunch timing risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverdose deaths\u003c\/td\u003e\n\u003ctd\u003e80,391 in 2024\u003c\/td\u003e\n\u003ctd\u003eSupports demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eX-waiver ended\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eAccess improved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExplores how external forces shape Aquestive Therapeutics, Inc. across Political, Economic, Social, Technological, Environmental, and Legal factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick PESTLE snapshot of Aquestive Therapeutics to simplify external risk review and speed up strategy discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, FDA filings, and financial statements to speed due diligence and let investors verify key Aquestive claims quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e4 marketed products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics’ revenue still depends on a few marketed products, so reimbursement cuts, supply issues, or softer demand can hit sales fast. In 2025, this kind of concentration risk kept the commercial base narrow, while new launches mattered to widen recurring revenue and reduce volatility. That makes product mix a key economic risk factor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. must fund formulation work, clinical studies, and FDA filings, so R\u0026amp;D can stay heavy for years before sales arrive. That makes margins sensitive, because drug development is capital intensive and often burns cash long before a launch scales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs and insurers can make or break Aquestive Therapeutics, Inc.’s script growth: they steer about 90% of U.S. prescriptions through formularies, prior auth, and rebates. For branded specialty and rescue drugs, those levers can cut net sales fast, even when list demand is strong. In 2025, access terms and gross-to-net discipline stayed central to revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiotech financing dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a development-stage specialty pharma company, Aquestive Therapeutics, Inc. depends on outside capital to fund trials and commercialization. That makes equity raises, debt terms, and licensing income key to pipeline progress, while higher rates in 2025 kept borrowing costs elevated and made dilution more likely if markets stayed tight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital access can speed or slow R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eDebt gets pricier when rates stay high\u003c\/li\u003e\n\u003cli\u003eLicensing cash helps fund the pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric competition risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeveral Aquestive Therapeutics, Inc. products compete with cheaper tablets, capsules, and sprays, so price cuts can slowly squeeze gross margin. Its film-delivery platform helps differentiate products, but it does not stop payer and channel pricing pressure. In a market where a 5% price drop can hit margin fast, competition stays a real risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCheaper substitutes cap pricing.\u003c\/li\u003e\n\u003cli\u003ePrice erosion can cut gross margin.\u003c\/li\u003e\n\u003cli\u003eFilm delivery helps, but not fully.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAquestive's 2025 Revenue Risk: PBM Power and Tight Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Aquestive Therapeutics, Inc. still faced economic pressure from narrow product concentration, so a reimbursement cut or softer demand could move revenue fast. PBMs and insurers controlled about 90% of U.S. prescriptions, which kept access terms and rebates central to net sales. High R\u0026amp;D spend and tight capital access also kept cash flow sensitive.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM control\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRate pressure\u003c\/td\u003e\n\u003ctd\u003eHigher borrowing costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eModel risk\u003c\/td\u003e\n\u003ctd\u003eNarrow revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAquestive Therapeutics, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis of Aquestive Therapeutics, Inc. you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnmet need in chronic disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnmet need is high in Aquestive Therapeutics, Inc.’s target areas: epilepsy affects about 50 million people worldwide, ALS about 30,000 in the U.S., and severe food allergy about 33 million Americans. These chronic or recurring conditions need fast, easier-to-use medicines, so simpler formats can improve adherence for patients and caregivers. That can also support physician adoption and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwallowing-friendly dosage forms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSwallowing-friendly dosage forms fit a real need: about 37% of adults and up to 90% of older adults report dysphagia, and pediatric pill-swallowing problems are common too. Oral soluble, sublingual, and buccal films can help in neurology and emergency use because they are easy to carry and use without water. That convenience can lift adherence, which matters when missed doses quickly hurt outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStigma in addiction care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStigma around opioid dependence can slow Suboxone starts and hurt persistence, even though medication-assisted treatment cut overdose risk by about 50% in large studies. In the U.S., only about 1 in 4 people with opioid use disorder get any treatment, so social acceptance still matters. Broader acceptance of treatment can improve access, retention, and outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCaregiver-led treatment decisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCaregiver-led decisions matter for Aquestive Therapeutics, Inc. because epilepsy, ALS, and emergency seizure care often depend on family or paid caregivers. In the United States, about 3.4 million people live with epilepsy, and ALS affects about 30,000 people, so ease of use can shape demand.\u003c\/p\u003e\n\u003cp\u003eProducts with simple administration and clear dosing steps are more likely to be chosen when a caregiver must act fast. In seizure emergencies, seconds matter, so instructions that reduce error can directly affect product preference and adherence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFamily and caregiver input drives choice\u003c\/li\u003e\n\u003cli\u003eSimple use can lift adoption\u003c\/li\u003e\n\u003cli\u003eClear steps matter in seizure emergencies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAging and chronic illness burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAging raises the burden of ALS, Parkinson’s disease, and chronic nausea, and that supports need for easier, patient-friendly dosing. Parkinson’s affects about 10 million people worldwide, and older adults often use several prescription drugs plus specialty care, which lifts demand for simpler formulations.\u003c\/p\u003e\n\u003cp\u003eQuesto? KYNMOBI already targets Parkinson’s “off” episodes, so Aquestive Therapeutics, Inc. has real-world proof that non-oral delivery can fit long-term care needs. ALS and nausea also point to patients who may struggle with swallowing, making fast-dissolve or other easy-use forms more relevant.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder patients need more medicines.\u003c\/li\u003e\n\u003cli\u003eParkinson’s scale is large and growing.\u003c\/li\u003e\n\u003cli\u003eSwallowing issues favor easy-use dosing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Need Markets Could Drive Aquestive Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSocial demand is strong for Aquestive Therapeutics, Inc. because epilepsy affects about 50 million people worldwide, ALS about 30,000 people in the U.S., and severe food allergy about 33 million Americans. Caregivers often choose the product, so simple, fast dosing matters. Stigma around opioid use disorder still slows starts and follow-through.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpilepsy\u003c\/td\u003e\n\u003ctd\u003e50M global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALS\u003c\/td\u003e\n\u003ctd\u003e30K U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFood allergy\u003c\/td\u003e\n\u003ctd\u003e33M U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral film platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.'s oral film platform uses soluble film drug delivery to support oral, sublingual, and buccal dosing, which can improve convenience and speed versus swallowed tablets. The format also helps differentiate products in crowded markets by avoiding the usual pill and capsule design. That edge matters as the company pushes film-based therapies beyond standard oral dosage forms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex molecule delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics' technology edge sits in complex molecule delivery across five programs: epinephrine, octreotide, diazepam, riluzole, and apomorphine-linked know-how. These drugs need tight control of stability and bioavailability, so formulation skill is a key barrier to entry. If delivery works, the platform can create strong product protection and support pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStability and packaging control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFilm products can absorb moisture and lose performance fast, so Aquestive Therapeutics, Inc. must prove tight packaging control and long shelf-life data before scale-up. In oral thin-film drugs, even small shifts in heat, humidity, or handling can change dose uniformity and disintegration time, which makes manufacturing consistency a hard gate.\u003c\/p\u003e\n\u003cp\u003eThat matters because any failure in stability can delay launches, trigger rework, and raise COGS. Strong barrier packaging, validated process controls, and repeatable batch output are critical if Aquestive Therapeutics, Inc. wants to move from pilot lots to reliable commercial supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty manufacturing know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. relies on tight control of coating, drying, cutting, and dose-uniformity; even small process shifts can break USP \u0026lt;905\u0026gt; content-uniformity limits, where the acceptance value is 15.0. That makes manufacturing know-how a real moat, because the same film tech must stay stable at scale and under FDA cGMP rules. \u003c\/p\u003e\n\u003cp\u003eThe company’s value chain depends on repeatable execution, not just formulation design, since a thin-film dose can fail if moisture, temperature, or cut size drift. In specialty dosage forms, technical transfer and process control are often the main barrier to entry. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrecision drives batch quality.\u003c\/li\u003e\n\u003cli\u003eSmall drift can trigger rejects.\u003c\/li\u003e\n\u003cli\u003eProcess know-how blocks rivals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline-platform reuse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. can reuse its PharmFilm platform across several drugs, so one delivery system can support new indications without starting from scratch. That can cut development time and help extend product life in neurology, allergy, and endocrine uses, including 2025-stage programs such as Anaphylm and Libervant.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReuse lowers new-platform risk\u003c\/li\u003e\n\u003cli\u003eSpeeds label expansion\u003c\/li\u003e\n\u003cli\u003eSupports lifecycle extension\u003c\/li\u003e\n\u003cli\u003eFits multiple therapeutic markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmFilm’s Precision Edge: Lower Risk, Faster Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc. depends on film-dose control, because heat, moisture, and cut precision can change uniformity and disintegration. Its PharmFilm platform can reuse one delivery system across multiple programs, which lowers technical risk and supports faster lifecycle expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMoisture control\u003c\/td\u003e\n\u003ctd\u003eCritical for shelf life\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcess control\u003c\/td\u003e\n\u003ctd\u003eNeeded for dose uniformity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform reuse\u003c\/td\u003e\n\u003ctd\u003eSupports new indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA CMC compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvery Aquestive Therapeutics, Inc. product must meet FDA current GMP and CMC rules, so film dose forms need tight batch control and validated processes. A single CMC gap can trigger Form 483 findings, warning letters, or launch delays, which matters when the FDA cleared 55 novel drugs in 2024 and still keeps a close review on complex dosage forms. For Aquestive Therapeutics, Inc., strong compliance is not optional; it is a launch gate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and exclusivity protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent and exclusivity protection is central to Aquestive Therapeutics, Inc.’s value because its oral and nasal delivery tech can be copied fast once protection weakens. A patent lapse or litigation can open the door to lower-cost rivals, which matters when the company is still scaling; it posted $50M+ in annual revenue in recent filings. For this kind of differentiated platform, legal durability can matter as much as clinical data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eControlled substance regulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eControlled substance rules hit Aquestive Therapeutics, Inc. hard because Suboxone contains buprenorphine, a DEA Schedule III drug, while diazepam is Schedule IV. That means tighter storage, prescribing, dispensing, and reporting controls, plus audit trails at every step. Any misstep can trigger FDA or DEA action, including fines, shipment holds, or distribution limits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDrug safety and labeling liability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrescription drugs need ongoing adverse-event monitoring, and label changes can follow new safety data. For Aquestive Therapeutics, Inc., a safety signal can mean boxed warnings, tighter use limits, or even withdrawal, which can hit sales fast. Litigation risk is still material in specialty pharma because one labeling dispute can trigger costly defense and settlement pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonitor adverse events after launch\u003c\/li\u003e\n\u003cli\u003eUpdate labels when signals appear\u003c\/li\u003e\n\u003cli\u003eExpect warning or access limits\u003c\/li\u003e\n\u003cli\u003eLitigation can raise cash burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePricing and reimbursement law\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePricing and reimbursement law is a key gate for Aquestive Therapeutics, Inc., because anti-kickback, rebate, and payer-contract rules can change how its products are sold and paid for. In 2025, Medicare Part D’s $2,000 out-of-pocket cap made government pricing rules even more important, since gross price can differ sharply from net realized price.\u003c\/p\u003e\n\u003cp\u003eFor Aquestive Therapeutics, Inc., legal compliance matters in sales, rebates, and market access talks with managed-care plans and public programs. Small contract or rebate errors can cut margin fast, so pricing teams need tight controls, audit trails, and clear payer terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnti-kickback risk can block sales.\u003c\/li\u003e\n\u003cli\u003eRebates drive net price lower.\u003c\/li\u003e\n\u003cli\u003ePublic programs shape reimbursement terms.\u003c\/li\u003e\n\u003cli\u003eCompliance supports market access execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA, DEA, and Patent Risk Could Move Aquestive Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegal risk for Aquestive Therapeutics, Inc. centers on FDA GMP, DEA controls, and patent defense; any CMC or scheduling slip can delay launches or cut access. Its 2025 revenue topped $50M, so even small legal hits can matter.\u003c\/p\u003e\n\u003cp\u003eIP protection is vital because oral and nasal delivery tech can be copied fast once patents fade.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA CMC\u003c\/td\u003e\n\u003ctd\u003eLaunch gate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEA\u003c\/td\u003e\n\u003ctd\u003eBuprenorphine Schedule III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$50M+ in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMoisture-sensitive packaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAquestive Therapeutics, Inc.’s film dosage forms need moisture-barrier packaging to protect quality, because humidity can hurt stability and dose performance. Humidity control in manufacturing and shipping matters, and barrier materials help keep the films intact through storage and transit. Packaging choices also affect waste, since stronger protection can cut spoilage but may add more material.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing energy use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDrying, coating, and controlled storage all draw steady power, so manufacturing energy use can be a real cost driver for Aquestive Therapeutics, Inc. Cutting kilowatt-hours lowers both utility spend and emissions at the same time. That matters more as pharma facilities face tighter reporting and cleaner-plant expectations from customers and regulators.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain disruption risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRaw materials, excipients, and packaging parts can be delayed by storms, port slowdowns, or transport bottlenecks, which can push back production and shipment. Climate events are now a real operating risk, so a single supplier or lane can tighten supply fast. Diversified sourcing across at least 2 qualified suppliers helps Aquestive Therapeutics, Inc. reduce that exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharmaceutical waste management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharmaceutical waste management matters for Aquestive Therapeutics, Inc. because unused medicines, rejected batches, and packaging waste must be handled under strict FDA and DEA rules, especially for controlled substances. In the U.S., healthcare waste is measured in millions of tons a year, so strong segregation and disposal controls help limit risk, cut compliance costs, and protect product quality. Tight waste controls also support ESG credibility because they show traceable handling, less landfill loss, and lower contamination risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControl unused and rejected product\u003c\/li\u003e\n\u003cli\u003eFollow DEA disposal rules closely\u003c\/li\u003e\n\u003cli\u003eTrack packaging waste by lot\u003c\/li\u003e\n\u003cli\u003eSupport compliance and ESG trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory ESG expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory ESG expectations are rising, and even a small pharma name like Aquestive Therapeutics, Inc. may need tighter disclosure on energy use, waste, and supply-chain controls. Investors now screen for ISSB-aligned reporting, and CDP had more than 23,000 companies disclose environmental data in 2024, so procurement, manufacturing, and site choices can face more scrutiny.\u003c\/p\u003e\n\u003cp\u003eThis can push Aquestive Therapeutics, Inc. to track emissions, vendor standards, and plant-level compliance more closely, even if spend is modest. The result is more discipline in reporting and fewer gaps in partner due diligence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore ESG reporting pressure from investors.\u003c\/li\u003e\n\u003cli\u003eSupplier checks can affect procurement.\u003c\/li\u003e\n\u003cli\u003eSite and manufacturing choices matter more.\u003c\/li\u003e\n\u003cli\u003eStronger disclosure lowers partner friction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvironmental Risks Shape Aquestive’s Production Resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvironmental risk for Aquestive Therapeutics, Inc. centers on moisture-sensitive films, energy-heavy drying, and waste control. Climate disruptions can also delay inputs, so dual sourcing and tight storage help protect output.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDP disclosure\u003c\/td\u003e\n\u003ctd\u003e23,000+ companies in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier buffer\u003c\/td\u003e\n\u003ctd\u003eAt least 2 qualified sources\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233974460681,"sku":"aqst-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/aqst-pestle-analysis.webp?v=1785711255","url":"https:\/\/dcfanalyst.com\/products\/aqst-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}